000			01461 a2200373 4500
005			20250512210711.0
264		0	_c19830527
008			198305s 0 0 eng d
022			_a0190-9622
024	7		_a10.1016/s0190-9622(83)70042-3 _2doi
040			_aNLM _beng _cNLM
100	1		_aKang, K
245	0	0	_aThymopoietin pentapeptide (TP-5) improves clinical parameters and lymphocyte subpopulations in atopic dermatitis. _h[electronic resource]
260			_bJournal of the American Academy of Dermatology _cMar 1983
300			_a372-7 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAdult
650	0	4	_aDermatitis, Atopic _xdrug therapy
650	0	4	_aDouble-Blind Method
650	0	4	_aHormones _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aImmunoglobulin E _xmetabolism
650	0	4	_aLeukocyte Count
650	0	4	_aLymphocytes _xdrug effects
650	0	4	_aMiddle Aged
650	0	4	_aPeptide Fragments _xtherapeutic use
650	0	4	_aThymopentin
650	0	4	_aThymopoietins _xtherapeutic use
650	0	4	_aThymus Hormones _xtherapeutic use
700	1		_aCooper, K D
700	1		_aHanifin, J M
773	0		_tJournal of the American Academy of Dermatology _gvol. 8 _gno. 3 _gp. 372-7
856	4	0	_uhttps://doi.org/10.1016/s0190-9622(83)70042-3 _zAvailable from publisher's website
999			_c6339491 _d6339491